Novaliq GmbH Strengthens Executive Management Team by Appointing Oliver Schlüter, PhD as Managing Director and CFO, and Hartmut Voss, PhD as CBO

HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH, a clinical stage specialty pharmaceutical company with a disruptive drug delivery technology platform transforming poorly soluble drugs into effective therapeutics for ophthalmology, announced today that Oliver Schlüter, PhD, has joined the company as Managing Director and Chief Financial Officer (CFO), and that Hartmut Voss, PhD, has been named Chief Business Officer (CBO).

"We are very pleased to strengthen our executive management team with Oliver Schlüter and Hartmut Voss."
Previously, Dr. Schlüter was CFO of CureVac GmbH. During his tenure at CureVac, he was vital to the transformation of the 70 employee R&D-driven company to a 170 employee customer centric and value focused corporation with several strategic partnerships and in-house manufacturing. Since his appointment in 2010, the company secured more than €200 million in funding and increased the company value more than tenfold to more than €1 billion. Dr. Schlüter has 20 years of professional experience within Finance and Life Sciences. He holds a PhD in computational finance and studied business administration.

Dr. Voss has 30 years of experience within Life Sciences and has spent more than 15 years as an entrepreneur, holding various senior management positions within the Biotechnology Industry. He is responsible for the scientific evaluation of biotechnology and biopharmaceutical companies at dievini Hopp BioTech holding GmbH & Co. KG. Following his studies in biology at the University of Kaiserslautern, Dr. Voss obtained his PhD from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. In 1997, he co-founded LION bioscience AG (now SYGNIS Pharma AG) and in 2004, Life Biosystems GmbH (now Molecular Health AG), where he held various senior management positions.

Welcoming Dr. Schlüter and Dr. Voss, Bernhard Günther, co-founder and Managing Director, CEO, says, "We are very pleased to strengthen our executive management team with Oliver Schlüter and Hartmut Voss." Friedrich von Bohlen und Halbach, PhD, co-founder and Managing Director of dievini Hopp BioTech holding GmbH & Co. KG, adds, "Their careers in the development of pharmaceutical products and transforming technology platforms into viable businesses add significant expertise to Novaliq. This will help the company's transformation to become a leading specialty pharma company within Ophthalmology."

About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical and drug delivery company with the mission to transform poorly soluble drugs into effective ocular therapeutics for both front and back of the eye. Novaliq's proprietary technology enhances the topical bio availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq's most advanced product is NovaTears® with CE-marking based on Novaliq's proprietary EyeSol® Technology. More on www.novaliq.com.

Contacts

Europe:
Novaliq GmbH
Bernhard Günther, +49-6221-502-5911
Managing Director, CEO
[email protected]
Oliver Schlüter, PhD, +49-6221-502-5955
Managing Director, CFO
[email protected]
or
USA:
Scotia Vision Consultants
Michael O'Rourke, +1-813-323-1438
[email protected]

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.